drugset / Trial / NCT04001413
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
Combination immune checkpoint inhibitor and DNA vaccine will result in clearance of HPV DNA biomarkers (oral and/or plasma) for patients with persistent HPV-16 E6/E7 DNA (HPV biomarker) after treatment with curative intent.
Timeline
- Start
- 2019-09-17
- Primary completion
- 2021-03-25
- Completion
- 2021-03-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Rocakinogene Sifuplasmid | Vaccine | — | Other |